acut
respiratori
tract
infect
arti
lead
caus
morbid
mortal
worldwid
frequent
reason
seek
medic
care
pathogen
predilect
either
upper
lower
respiratori
tract
may
move
compart
etiolog
divers
led
high
viral
heterogen
also
compris
bacteria
healthrel
burden
acut
respiratori
tract
infect
signific
defin
popul
like
young
elderli
chronic
ill
underli
comorbid
eg
heart
lung
diseas
diabet
malnourish
immunocompromis
eg
transplant
recipi
hivinfect
individu
certain
pathogen
includ
influenza
ab
viru
human
orthopneumoviru
also
known
respiratori
syncyti
viru
bordetella
pertussi
convent
requir
contact
isol
hospit
patient
detect
avoid
institut
spread
fast
detect
identif
essenti
infect
control
effect
acut
respiratori
sign
symptom
specif
singl
pathogen
detect
allow
multipl
agent
simultan
detect
may
signific
impact
diseas
manag
patient
abil
rapidli
accur
rule
respiratori
pathogen
support
optim
overal
care
eg
hospit
admiss
therapi
select
eg
termin
unnecessari
antimicrobi
target
use
antivir
agent
public
health
perspect
syndrom
respiratori
infect
test
shown
use
tool
season
sporad
outbreak
surveil
prepared
support
effect
manag
health
care
resourc
thu
respiratori
virus
potenti
role
increasingli
acknowledg
use
multiplex
pcr
test
recommend
sinc
decemb
infecti
diseas
societi
america
immunocompromis
popul
present
arti
symptom
also
suggest
popul
result
taken
account
improv
patient
manag
studi
describ
first
multicent
evalu
clinic
perform
characterist
qiastat
respiratori
panel
qiastat
rp
qiagen
hilden
germani
respiratori
sampl
compar
filmarray
respiratori
panel
assay
filmarray
rp
marci
l
etoil
franc
discrep
test
perform
respiratori
panel
allplex
rp
seegen
seoul
south
korea
two
geograph
set
europ
studi
design
observ
prospectiveretrospect
studi
aim
test
qiastat
rp
pathogen
fresh
frozen
sampl
studi
perform
two
clinic
site
locat
denmark
germani
depart
clinic
microbiolog
univers
hospit
hvidovr
copenhagen
denmark
test
respiratori
sampl
collect
univers
transport
media
utm
sampl
prospect
collect
enrol
period
februari
februari
depart
clinic
microbiolog
univers
hospit
bonn
germani
test
protocol
compliant
retrospect
clinic
sampl
januari
march
sampl
collect
influenza
season
decemb
flock
swab
sampl
utm
residu
sampl
store
sampl
test
qiastat
rp
qiagen
hilden
germani
filmarray
rp
marci
etoil
franc
serv
refer
method
discrep
two
test
method
clinic
site
resolv
allplex
rp
seegen
seoul
south
korea
clinic
site
bonn
test
clinic
site
perform
train
laboratori
personnel
shown
profici
method
residu
respiratori
sampl
nasopharyng
flock
swab
utm
copan
brescia
itali
receiv
routin
bacteri
viral
test
patient
includ
studi
sampl
enrol
consecut
accord
instrument
capac
clinic
sampl
includ
two
studi
site
meet
follow
inclus
criteria
respiratori
sampl
collect
util
flock
swab
copan
brescia
itali
place
utm
sent
viral
andor
bacteri
test
residu
volum
includ
sampl
sampl
test
qiastat
rp
filmarray
rp
within
day
collect
store
within
minut
thaw
store
c
sampl
anonym
assign
studi
number
link
patient
demograph
inform
includ
age
sex
hospit
statu
gener
practic
hospit
pediatr
hospitalward
intens
care
unit
sampl
collect
institut
review
board
irb
approv
protocol
includ
waiver
inform
consent
use
residu
anonym
sampl
protocol
approv
ethikkommiss
der
medizinischen
der
rheinischen
bonn
approv
de
videnskabsetisk
komit
center
sundh
region
hovedstaden
approv
qiastat
dx
system
new
highli
multiplex
platform
integr
nucleic
acid
extract
multiplex
rtrealtim
pcr
detect
qiastat
rp
catalogu
number
design
run
qiastat
diagcor
analyz
test
respiratori
sampl
individu
sign
symptom
acut
respiratori
tract
infect
qiastat
rp
cartridg
contain
full
process
intern
control
ic
bacteriophag
includ
dri
format
get
automat
rehydr
upon
sampl
load
ic
verifi
step
analysi
process
test
includ
sampl
resuspensionhomogen
lysi
nucleic
acid
purif
revers
transcript
pcr
cartridg
two
distinct
load
port
inocul
directli
dri
swab
transport
medium
brief
sampl
homogen
vigor
invers
vial
utm
transfer
assay
cartridg
use
provid
transfer
pipett
inocul
cartridg
place
instrument
test
start
automat
ran
minut
upon
complet
test
eject
cartridg
analyz
interpret
result
display
test
summari
analyz
also
report
error
may
occur
process
amplif
curv
cycl
threshold
ct
valu
view
detect
pathogen
ic
report
print
export
extern
usb
storag
devic
analyz
bidirect
connect
laboratori
inform
system
qiastat
dx
system
consist
one
four
analyt
modul
catalogu
number
plu
one
analyz
modul
catalogu
number
allow
time
independ
parallel
test
one
sampl
per
modul
qiastat
rp
detect
viral
four
bacteri
pathogen
includ
human
mastadenoviru
ag
formerli
adenoviru
primat
bocaparvoviru
formerli
bocaviru
human
coronaviru
differenti
human
metapneumoviru
ab
hmpv
rhinovirusenteroviru
influenza
viru
subtyp
subtyp
influenza
b
viru
human
respiroviru
human
orthorubulaviru
formerli
human
parainfluenza
viru
type
human
orthopneumoviru
mycoplasma
pneumonia
legionella
pneumophilia
bordetella
pertussi
chlamydia
pneumonia
qiastat
rp
test
consid
valid
test
complet
normal
control
pass
result
influenza
viru
report
influenza
viru
subtyp
influenza
viru
subtyp
influenza
viru
pandem
influenza
case
influenza
viru
respect
subtypestrain
detect
case
subtyp
detect
influenza
viru
report
influenza
viru
subtyp
studi
conduct
investig
use
iuo
version
qiastat
rp
final
cemark
qiastat
rp
ident
iuo
panel
use
studi
except
result
chlamydia
pneumonia
target
report
pend
regulatori
clearanc
filmarray
rp
multiplex
sampletoansw
pcr
panel
test
viral
bacteri
pathogen
nasopharyng
swab
utm
time
sampl
volum
requir
test
approxim
two
minut
handsontim
setup
test
system
consist
one
eight
modul
biofir
flimarray
torch
salt
lake
citi
utah
usa
allow
time
independ
parallel
test
one
sampl
per
modul
test
run
approxim
minut
report
print
export
extern
usb
storag
devic
analyz
bidirect
connect
laboratori
inform
system
filmarray
rp
detect
viral
three
bacteri
pathogen
includ
human
mastadenoviru
ag
human
coronaviru
differenti
human
metapneumoviru
ab
hmpv
rhinovirusenteroviru
influenza
viru
subtyp
subtyp
influenza
b
viru
human
respiroviru
human
orthorubulaviru
human
orthopneumoviru
mycoplasma
pneumonia
bordetella
pertussi
chlamydia
pneumonia
human
coronaviru
filmarray
rp
assay
accept
correct
pathogen
includ
panel
allplex
rp
sampl
yield
discord
result
qiastat
rp
filmarray
rp
discrep
test
allplex
rp
assay
allplex
rp
rtpcr
assay
test
viral
seven
bacteri
pathogen
nasopharyng
swab
nasopharyng
aspir
bronchoalveolar
lavag
time
allplex
rp
run
seegen
workflow
consist
modul
nucleic
acid
extract
pcr
setup
pcr
thermocycl
comput
interpret
report
total
sampletoansw
time
less
one
day
allplex
rp
detect
human
mastadenoviru
ag
primat
bocaparvoviru
human
coronaviru
differenti
human
metapneumoviru
ab
hmpv
rhinoviru
enteroviru
influenza
viru
subtyp
subtyp
influenza
b
viru
human
respiroviru
human
orthorubulaviru
human
orthopneumoviru
b
mycoplasma
pneumonia
bordetella
pertussi
bordetella
parapertussi
legionella
pneumophila
chlamydia
pneumonia
streptococcu
pneumonia
haemophilu
influenza
allplex
rp
assay
use
compar
method
primat
bocaparvoviru
analyt
includ
filmarray
rp
panel
allplex
rp
result
accept
correct
sensit
specif
report
qiastat
rp
could
compar
combin
result
filmarray
rp
allplex
rp
result
report
true
posit
tp
fals
posit
fp
fals
neg
fn
true
neg
tn
result
binomi
twosid
confid
interv
calcul
use
wilson
score
method
human
coronaviru
primat
bocaparvoviu
result
compar
calcul
posit
percent
agreement
ppa
neg
percent
agreement
npa
result
qiastat
rp
either
filmarray
rp
allplex
rp
avail
primat
bocaparvoviru
includ
target
filmarray
rp
human
coronaviru
includ
allplex
rp
make
imposs
determin
sensit
specif
two
target
accordingli
overal
agreement
also
report
ppa
npa
sensit
specif
determin
target
ppa
repres
often
new
test
nt
agre
nonrefer
standard
nr
calcul
ppa
nt
nr
posit
nt
nr
posit
nt
neg
nr
posit
wherea
npa
calcul
npa
nt
nr
neg
nt
nr
neg
nt
posit
nr
neg
patient
includ
studi
gender
distribut
almost
equal
femal
patient
male
patient
patient
younger
six
year
patient
six
year
patient
year
patient
year
older
age
inform
avail
six
patient
major
sampl
refer
test
gener
practition
sampl
hospit
patient
pediatr
hospitalward
two
sampl
came
intens
care
unit
patient
present
sign
symptom
acut
respiratori
tract
infect
qiastat
rp
detect
one
potenti
pathogen
test
sampl
tabl
total
pathogen
tabl
multipl
pathogen
detect
posit
sampl
highest
number
pathogen
detect
singl
sampl
five
human
respiroviru
human
orthorubulaviru
human
coronaviru
rhinoenteroviru
primat
bocaparvoviru
major
multipl
infect
sampl
contain
two
pathogen
case
sampl
qiastat
rp
detect
bacteri
pathogen
sampl
sampl
bacteria
detect
remain
nine
sampl
addit
viral
pathogen
detect
four
sampl
two
pathogen
four
sampl
three
pathogen
one
sampl
four
pathogen
number
potenti
pathogen
detect
qiastat
rp
coinfect
hospit
age
group
present
tabl
frequent
detect
pathogen
human
orthopneumoviru
detect
sampl
came
patient
less
year
age
second
common
pathogen
influenza
viru
detect
sampl
equal
distribut
strain
rhinoenteroviru
detect
sampl
influenza
b
viru
detect
sampl
highlight
activ
influenza
b
viru
season
earli
specimen
valid
result
obtain
initi
qiastat
rp
test
five
sampl
invalid
first
qiastat
rp
test
compris
one
run
abort
analyz
three
run
softwar
error
one
run
intern
control
fail
amplifi
five
sampl
retest
qiastat
rp
yield
valid
result
second
qiastat
rp
test
perform
characterist
individu
qiastat
rp
target
discrep
resolut
present
tabl
perform
characterist
discrep
resolut
present
tabl
resolut
discrep
test
qiastat
rp
filmarray
rp
agre
detect
pathogen
sampl
tabl
pathogen
except
human
mastadenoviru
ag
rhinoenteroviru
hmpv
influenza
viru
subtyp
human
respiroviru
agreement
excel
tabl
human
respiroviru
influenza
viru
subtyp
total
number
posit
sampl
least
one
method
nine
five
respect
human
mastadenoviru
ag
qiastat
rp
filmarray
rp
agre
posit
sampl
initi
posit
sampl
tabl
discrep
test
sensit
qiastat
rp
tabl
rhinoenteroviru
qiastat
rp
filmarray
rp
agre
posit
sampl
initi
posit
sampl
discrep
test
sensit
qiastat
rp
hmpv
qiastat
rp
filmarray
rp
agre
posit
sampl
initi
posit
sampl
discrep
test
sensit
resolut
discrep
test
allplex
rp
total
pathogen
result
consid
true
posit
tabl
qiastat
rp
detect
overal
ppa
ci
discrep
test
overal
npa
qiastat
rp
ci
twentytwo
pathogen
detect
filmarray
rp
detect
qiastat
rp
tabl
fourteen
also
detect
allplex
rp
consid
true
neg
leav
pathogen
detect
fals
neg
tabl
thirtynin
pathogen
detect
qiastat
rp
detect
filmarray
rp
tabl
twentyon
also
detect
allplex
rp
consid
fals
posit
tabl
three
pathogen
detect
filmarray
rp
detect
qiastat
rp
detect
singl
infect
sampl
addit
two
pathogen
detect
qiastat
rp
detect
doubl
infect
sampl
five
pathogen
involv
rhinoenteroviru
three
human
mastadenoviru
ag
one
human
orthopneumoviru
one
five
pathogen
detect
discrep
method
allplex
rp
remain
pathogen
detect
qiastat
rp
detect
filmarray
rp
sampl
two
pathogen
three
pathogen
one
hmpv
one
influenza
viru
subtyp
one
human
orthopneumoviru
detect
discrep
method
ad
total
fals
neg
pathogen
qiastat
rp
detect
pathogen
detect
filmarray
rp
pathogen
singl
infect
sampl
detect
pathogen
rhinoenteroviru
n
ct
valu
influenza
b
viru
n
ct
valu
influenza
viru
subtyp
n
ct
valu
influenza
viru
subtyp
n
ct
valu
human
orthopneumoviru
n
ct
valu
human
mastadenoviru
ag
n
ct
valu
influenza
viru
detect
subtyp
sampl
could
discrep
test
due
insuffici
residu
volum
accordingli
consid
fals
posit
qiastat
rp
one
addit
singleinfect
pathogen
rhinoenteroviru
consid
fals
posit
result
could
confirm
posit
discrep
test
remain
eight
singleinfect
pathogen
confirm
posit
discrep
method
thu
consid
true
posit
tabl
remain
pathogen
detect
qiastat
rp
detect
filmarray
rp
sampl
two
pathogen
nineteen
pathogen
ten
rhinoenteroviru
ct
valu
three
human
mastadenoviru
ag
ct
valu
one
human
orthorubulaviru
ct
valu
one
mycoplasma
pneumonia
ct
valu
two
primat
bocaparvoviru
ct
valu
two
human
coronaviru
ct
valu
could
confirm
discrep
test
thu
consid
fals
posit
total
fals
posit
pathogen
tabl
remain
pathogen
confirm
allplex
rp
sampl
two
pathogen
three
human
mastadenoviru
ag
ct
valu
three
rhinoenteroviru
ct
valu
human
orthopneumoviru
ct
valu
two
influenza
viru
subtyp
one
influenza
viru
subtyp
avail
ct
valu
possibl
assess
sensit
qiastat
rp
legionella
pneumophila
influenza
viru
subtyp
organ
detect
method
primat
bocaparvoviru
detect
qiastat
rp
five
specimen
contain
least
one
potenti
pathogen
allplex
rp
confirm
detect
primat
bocaparvoviru
three
five
specimen
primat
bocaparvoviru
includ
panel
refer
method
result
list
separ
express
ppanpa
studi
demonstr
first
time
clinic
perform
new
qiastat
rp
assay
detect
respiratori
pathogen
comparison
filmarray
rp
overal
ppa
npa
discrep
test
ci
ci
respect
gener
qiastat
rp
assay
show
excel
agreement
filmarray
rp
pathogen
includ
qiastat
rp
test
menu
except
rhinoenteroviru
tp
tn
sampl
influenza
viru
subtyp
tp
tn
sampl
hmpv
tp
tn
sampl
qiastat
rp
show
sensitivityppa
specificitynpa
tabl
reason
discord
result
rhinoenteroviru
known
may
potenti
explain
differ
diagnost
test
target
differ
genet
region
rhinoenteroviru
genom
ct
valu
pathogen
target
present
discrep
qiastat
posit
rp
filmarray
rp
neg
sampl
detect
qiastat
ct
valu
rang
may
consid
weakli
posit
three
target
detect
qiastat
rp
posit
filmarray
rp
neg
target
ct
valu
one
human
orthopneumoviru
ct
two
rhinoenteroviru
ct
thu
strong
posit
sampl
would
benefici
resolv
discrep
result
sequenc
potenti
would
clarifi
discord
result
rhinoenteroviru
possibl
qiastat
rp
filmarray
rp
assay
perform
seal
samplestoansw
cartridg
construct
prevent
access
sampl
materi
remain
cartridg
qiastat
rp
assay
requir
one
manual
pipet
step
load
patient
sampl
test
cartridg
test
cartridg
id
patientsampl
id
enter
onboard
scanner
total
assay
time
approxim
minut
qiastat
dx
diagcor
analyz
offer
small
footprint
traceabl
intern
inhibit
control
amplif
curv
well
ct
valu
low
mainten
requir
low
failur
rate
well
seamless
connect
integr
hospit
laboratori
inform
system
addit
qiastat
dx
diagcor
analyz
offer
access
amplif
curv
ct
valu
detect
pathogen
target
qiastat
rp
assay
cartridg
onboard
wet
dri
reagent
buildin
amplif
inhibit
control
detect
pathogen
total
separ
reaction
chamber
offer
direct
dri
swab
test
option
via
separ
cartridg
input
port
store
room
temperatur
qiastat
rp
ce
ivd
mark
fda
approv
pend
syndrom
diagnost
approach
arti
may
provid
multipl
benefit
institut
eg
prudent
use
side
room
isol
facil
reduc
prescript
antimicrobi
target
use
antivir
benefit
partli
describ
previou
public
trabattoni
et
al
report
signific
reduct
emerg
depart
ed
length
stay
well
signific
reduct
hospit
rate
patient
test
aler
influenza
assay
ed
hansen
et
al
report
posit
impact
admitt
rate
well
total
cost
roch
liat
influenza
test
ed
set
brendish
et
al
report
encourag
find
poc
test
respiratori
virus
studi
show
test
associ
reduc
length
hospit
stay
result
singl
dose
brief
cours
antibiot
well
improv
influenza
detect
antivir
use
howev
understand
full
impact
patient
manag
syndrom
test
approach
arti
well
costbenefit
requir
prospect
outcom
studi
studi
would
also
provid
inform
regard
patient
popul
benefit
respiratori
tract
syndrom
test
ad
benefit
syndrom
test
compar
select
target
test
eg
influenza
ab
viru
human
orthopneumoviru
hmpv
bordetella
pertussi
combin
hereof
studi
sever
limit
first
studi
design
epidemiolog
studi
includ
clinic
sampl
collect
consecut
detect
coinfect
rate
frequenc
differ
pathogen
coinfect
sampl
may
reflect
actual
coinfect
rate
patient
popul
time
sampl
collect
second
sever
pathogen
eg
coronavirus
b
pertussi
c
pneumonia
parainfluenzaviru
detect
clinic
sampl
perform
qiastat
rp
assay
detect
pathogen
uncertain
conclus
first
clinic
studi
new
qiastat
rp
assay
perform
two
diagnost
laboratori
provid
clinic
sampl
analysi
observ
excel
diagnost
accuraci
qiastat
rp
assay
compar
compar
filmarray
rp
qiastat
rp
assay
could
potenti
impact
posit
antimicrobi
stewardship
hospit
admitt
use
side
room
contact
isol
facil
